anti-atherogenic and antioxidant protein. It plays an important role in reverse cholesterol transport and protects LDL against oxidation (4) . Paraoxonase (PON)-1 and PON3 are antioxidant enzymes that are mainly synthesised by the liver, and they are bound to HDL in serum (5) . PON1 prevents LDL oxidation and foam-cell formation, thereby inhibiting atherosclerosis development (6) . Also, PON3 prevents mildly oxidized LDL formation and, therefore, monocyte chemotactic activity (7, 8) . Oxidized LDL, in turn, can inactivate PON activity (2) . It has been shown that ApoA1, PON1 and PON3 are antioxidant, anti-inflammatory and anti-atherosclerotic proteins, and they play important roles in the atheroprotective activities of HDL (4, 5) . A large number of studies have reported that dietary antioxidants may decrease the development of atherosclerosis. Possible mechanisms of dietary antioxidants include inhibition of LDL oxidation and preservation or increase of PON enzyme activities (3) . Caffeine, a methylxanthine, is the most widely consumed substance in the human diet. This psychoactive alkaloid is found primarily in the seeds, nuts, and leaves of some plants. It is also readily available in a variety of foods and beverages that we consume in our daily lives, such as chocolate, coffee, tea and energy drinks (9) . Well-known effects of caffeine on the body include increased motor and mental activities through the stimulation of the central nervous system, increased heart rate and diuresis. Caffeine is used to mitigate sleepiness, to suppress appetite, to treat apnoea in premature infants, to enhance performance and for headache therapy (10) . Despite several previous reports of the effect of caffeine on atherosclerosis (11) (12) (13) , no study has ever been performed to specifically examine the effects of caffeine on PON enzymes. Although the effect of caffeine on serum ApoA1 levels has been reported by some investigators (14-16), we have not encountered any studies that investigate the effects of caffeine on liver ApoA1 protein levels. The aim of the present study was to investigate the dose-dependent effects of caffeine on ApoA1, PON1 and PON3 protein levels in the liver. Because ApoA1, PON1 and PON3 are primarily synthesised by the liver, we chose human-derived liver (HepG2) cells. HepG2 cells are useful tools in the understanding of hepatic protein biosynthesis and retain many biological characteristics of hepatocytes (17) . Previous studies also used HepG2 cells to investigate ApoA1, PON1 and PON3 expressions in the liver (8, 18) . It has been reported that plasma caffeine concentrations are usually between 2-10 mg/L (approximately 10-50 μM) in adults, depending on daily coffee consumption. Toxic effects are observed at a plasma caffeine concentration higher than 40 mg/L (approximately 200 μM) (19, 20) . Therefore, for this study we investigated the effects of caffeine concentrations at 10, 50 and 200 μM.
MATERIALS AND METHODS

Chemicals
Human HepG2 cells were purchased from ATCC (Middlesex, UK). Caffeine was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Minimum essential medium (MEM) with glutamine, fetal bovine serum, antibiotic-antimycotic, sodium pyruvate, trypsin-ethylenediaminetetraacetic acid and horseradish peroxidase (HRP) chemiluminescent substrate were purchased from Thermo Fisher (Waltham, MA USA). PON1, PON3, alpha tubulin primary antibodies and goat antimouse IgG H&L HRP secondary antibody were purchased from Abcam (Cambridge, UK). ApoA1 primary antibody was purchased from Novus Biologicals Inc. (Littleton, CO, USA). The radioimmunoprecipitation assay (RIPA) lysis buffer system was purchased from Santa Cruz (Heidelberg, Germany). The polyvinylidene fluoride (PVDF) membrane was purchased from Bio-Rad (Hercules, CA, USA). Other chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA) or Merck (Darmstadt, Germany). All reagents were of analytical grade.
Cell culture and experimental design
This study was approved by the ethics committee of Trakya University School of Medicine (TÜTF-GOKAEK 2014/123, date of approval: 25 June 2014). HepG2 cells were cultured in MEM with glutamine containing 10% foetal bovine serum, 1% sodium pyruvate and 1% antibiotic-antimycotic (Thermo Fisher catalog number: 15240062) in a humidified environment at 37 °C and a 5% CO 2 atmosphere. HepG2 cells were divided into four groups; control cells (cultured in medium without caffeine for 24 hours), 10 μM caffeine-treated cells (cultured with 10 μM of caffeine for 24 hours), 50 μM caffeine-treated cells (cultured with 50 μM of caffeine for 24 hours) and 200 μM caffeine-treated cells (cultured with 200 μM of caffeine for 24 hours). For each group, the caffeine was dissolved in media. All of the experiments were repeated at least three times.
Cell viability assays
The effect of caffeine on cell viability was evaluated using the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (21). 1.5x10 4 cells were seeded into 96-well plates. Cells were treated with caffeine (10, 50 and 200 mM) for 24 hrs. At the end of treatment, media were removed and 10 µL of MTT (5 mg/mL) were dissolved in phosphatebuffered saline, and 100 µL of medium without phenol red were then added to each well. Cells were then incubated for 4 hrs in a humidified environment at 37 °C and a 5% CO 2 atmosphere. MTT-containing medium was then removed. Formazan crystals, formed by MTT reduction, were dissolved using 200 µL dimethyl sulfoxide and 25 µL Sorensen buffer (0.1 M glycine, 0.1 M sodium chloride, pH 10.5). The optical density of plates was measured using a microplate reader at 570/630 nm. The optical density of each sample was then compared with the mean optical density value of the control group.
Western blot analysis of PON1 and PON3 proteins
Cells were seeded into a 75 cm 2 flask. After the cells reached 70-80% confluence, they were treated with caffeine (10, 50 and 200 mM) for 24 hours. Following the treatments, cells were scraped with RIPA lysis buffer system. Samples were homogenized and then centrifuged at 4 °C for 10 minutes at 15.000×g. Supernatants were used for protein determination and western blotting. Protein concentrations were measured according to Lowry et al. (22) . 10 mg total protein for PON1 and 30 mg total protein for PON3 and ApoA1 were separated by sodium dodecyl sulfatepolyacyrlamide gel (4-8%) electrophoresis. With a semidry blotting system, proteins were transferred to a PVDF membrane. Membranes were blocked by incubating them with skim milk powder (5%) for 1 hour at room temperature. After blocking, membranes were incubated with monoclonal primary antibodies (PON1: 1/500 dilution, PON3: 1/2.000 dilution and ApoA1: 1/1.000 dilution) overnight at 4 °C and then with secondary antibody (HRP goat anti-mouse: 1/10.000 dilution) at room temperature for one hour. Protein bands were visualised by using an electrochemiluminescence (ECL) detection system with an HRP chemiluminescent substrate, and the bands were quantified using Image J (23) . Results were calculated relative to alpha-tubulin as the loading control, and they were expressed as fold changes relative to the control for each blot.
Statistical analysis
Results were given as means ± standard deviation. The one-way analysis of variance (ANOVA) test was used to compare the biochemical parameters among the groups. The Tamhane posthoc test was used for multiple comparisons when a significant difference was obtained with the one-way ANOVA. SPSS 20.0 (IBM SPSS Inc., Chicago, IL, USA) statistical software was used for the statistical analysis; a p<0.05 was considered statistically significant.
RESULTS
The mean percentage of cell viabilities of caffeine-treated groups was 107% for 10 µM caffeine-treated cells, 100% for 50 µM caffeine-treated cells and 84% for 200 µM caffeinetreated cells. Cell viability in those treated with 200 µM of caffeine was significantly lower than other groups (p<0.001 for all) (Figure 1 ). ApoA1 protein levels of the caffeine-treated groups were 1.25-fold, 1.32-fold and 1.15-fold higher for the cells exposed to 10, 50 and 200 µM of caffeine, respectively. The ApoA1 protein levels in the 50 µM caffeine-treated cells were significantly increased compared to those in the control cells (p<0.05 for both) (Table 1, Figure 2) . The PON1 protein levels of the caffeine-treated cells were 1.15-fold, 1.43-fold and 1.25-fold higher for the cells exposed to 10, 50 and 200 µM of caffeine, respectively. The PON1 protein levels in the 50 and 200 µM caffeine-treated cells were significantly increased compared to the protein levels in the control cells (p<0.05 for both) (Table 1, Figure 3) . The PON3 protein levels of the caffeine-treated groups were 1.02-fold, 1.05-fold and 1.01-fold higher for the cells exposed to 10, 50 and 200 µM of caffeine, respectively. There were no significant differences between PON3 protein levels for any of the groups (p>0.05 for all) (Table 1, Figure 4) . Results are expressed as the mean ± standard deviation of six samples from six independent experiments for each caffeine concentration; ApoA1, PON1 and PON3 protein levels were quantified by normalising to the levels of alpha tubulin and they are given as fold change relative to the control for each independent experiment; One-way analysis of variance with a Tamhane post-hoc test were used for statistical analyses; *: p<0.05, compared with control Sayılan Özgün et al. Caffeine Increases ApoA1 and PON1 but not PON3
DISCUSSION
Caffeine has a variety of pharmacological and cellular responses in biological systems. Some well-known effects of caffeine include central nervous system and cardiac muscle stimulation, diuresis and smooth muscle relaxation (10) . It is known that caffeine has several mechanisms of action. The most prominent one is reversibly binding to the adenosine receptor to block its action. Caffeine promotes wakefulness by this mechanism (10, 24 (11) reported that daily caffeine intake increases total blood cholesterol and LDL cholesterol levels, but decreases HDL cholesterol levels. It has been reported that caffeine does not change serum ApoA1 levels (14) , and there is no association between caffeine intake and coronary and carotid atherosclerosis (13) . On the other hand, it has been reported that caffeine increases serum ApoA1 levels, which is the major structural and functional protein of HDL (15,16). Yukawa et al. (26) also reported that coffee ingestion resulted in a decrease in total serum cholesterol, LDL cholesterol and malondialdehyde levels and in the susceptibility of LDL to oxidation. Taking into consideration these studies, in the present study we examined the dose-dependent effects of caffeine on liver PON1, PON3 and ApoA1 protein levels, and we evaluated a possible relationship between caffeine and atherosclerosis. We that reported toxic effects of caffeine at plasma concentrations of caffeine that were higher than 200 μM (19) . For the first time, we investigated the effects of caffeine on liver ApoA1 protein levels and found that 50 mM of caffeine significantly increased ApoA1 protein level in HepG2 cells. This finding is supported by previous studies that reported increases in serum ApoA1 levels caused by caffeine (15, 16) . Our study is also the first report to investigate the effects of caffeine on the PON1 enzyme. In this study, we found that both 50 mM and 200 mM of caffeine significantly increased PON1 protein levels in HepG2 cells. Other studies have reported that PON1 protein levels and activity are decreased in ApoA1 knock-out mice (27) , and the overexpression of ApoA1 increases PON1 activity in transgenic mice (28) . The regulation of PON1 enzyme is linked to HDL and ApoA1 modulation (5) . The findings reported in these studies are supported by the findings of our study, in which 50 mM of caffeine significantly increased PON1 protein and ApoA1 levels. A plasma concentration of 50 mM of caffeine, which is equal to the average plasma caffeine concentration of healthy individuals who consume coffee, may decrease the risk of atherosclerosis by increasing liver ApoA1 and PON1 protein levels. In the present study, 200 mM of caffeine, which is the plasma concentration of caffeine at which toxicity has been observed, decreased cell viability but increased PON1 protein level of HepG2 cells; this was a surprising result. Caffeine has been reported to exhibit both antioxidant and pro-oxidant properties (25) . Ikeda et al. (29) reported that high glucose induces PON1 protein levels in cultured hepatocytes, and that increasing PON1 protein levels may be a compensatory mechanism in diabetes. Our results, which were similar to those of Ikeda et al. (29) , suggest that an increase in PON1 protein levels in cells treated with 200 μM of caffeine may be a cell's defence mechanism against caffeine toxicity in the liver. In the present study, the effects of caffeine on the PON3 enzyme were also investigated for the first time. We demonstrated that exposure to caffeine does not significantly change PON3 protein levels at non-toxic (10 and 50 μM) or toxic (200 μM) plasma concentrations. This finding indicates that caffeine may not have an effect on the regulation of PON3 protein level. This finding is important because it indicates that the regulation of the PON3 enzyme may be different from that of the PON1 enzyme, even though they are members of the same gene family. This finding is in agreement with the finding of Reddy et al. (8) , who reported that while PON1 is regulated by oxidized lipids, PON3 is not regulated by oxidized lipids. It is also in agreement with our previous study, which indicated that PON3 is more sensitive to lipoic acid than PON1 in diabetic rats (30) . Further research should address these mechanisms.
In conclusion, our study showed that caffeine does not change PON3 protein levels, but it increases both ApoA1 and PON1 protein levels in liver cells. According to our results, caffeine may reduce atherosclerosis risk by increasing liver ApoA1 and PON1 protein levels. A limitation of this study is that we used an immortal hepatoma cell line instead of hepatocytes. Also, we only investigated ApoA1, PON1 and PON3 enzymes in liver cells; we did not consider other factors that are related to atherosclerosis in the liver or in other tissues such as endothelium and blood. Therefore, this in vitro study needs to be supported by future animal and human studies. 
